Pharma Deals Review, Vol 2010, No 2 (2010)

Font Size:  Small  Medium  Large

AstraZeneca and Rigel in a US$1.2 B Deal for Rheumatoid Arthritis

Taskin Ahmed

Abstract


AstraZeneca has entered the rheumatoid arthritis market by agreeing to develop and commercialise Rigel’s rheumatoid arthritis drug, R788, that is about to enter Phase III clinical trials.



Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.